Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

News SummaryMost relevantAll newsSector newsTweets

Allergan plc Ordinary Shares (NYSE:AGN)’s Botox Gets FDA Approval For Third Indication

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 04:15pm CEST

Allergan plc Ordinary Shares (NYSE:AGN)’s Botox has received the approval of the U.S. Food and Drug Administration for a third indication – improving the facial appearance of adults who have particular forehead lines. Other indications for which the FDA has given approval for Botox include the treatment of glabellar lines and crow’s feet. This now makes Botox the sole neurotoxin approved for use in treating three distinct facial areas.

The decision to approve Botox for a third indication came after two clinical trials where the effectiveness of the treatment was compared to a placebo within a period of 30 days. In the first trial the primary endpoint was met by 61% of participants.

Aesthetics market

According to the chief executive officer of Allergan, Brent Saunders, the FDA approval will give the pharmaceutical company yet another opportunity in the aesthetics market which in his own words is the world’s best market.

“It’s high-quality, it’s cash-pay, it’s global. We are just at the initial stages of market development in the U.S. and almost every market in the world. So we have very high conviction around the sustainability,” Saunders is quoted as saying in an earnings call earlier in the year.

In this year’s first half, Botox generated approximately $1.53 billion in sales. This was an improvement of 12.7% compared to a year ago and was largely driven by strong demand. Now approved for the treatment of forehead lines, sales should rise even higher.

Body contouring

To bolster Allergan’s lineup in the aesthetics market, the pharmaceutical giant earlier in the year indicated that it was acquiring Zeltiq, a body contouring firm, at a price of $2.47 billion. Earlier in the year Allergan got Rhofade, a new rosacea treatment, approved. Three months ago the treatment had notched a familiarity rate of 75% among practices.

Additionally Allergan is involved in the development of Botox as a solution or particular medical cases such as prevention of chronic migraines. In Allergan’s line-up of aesthetics treatments the one product that has not been performing well is Kybella, a chin fat-buster.

On Wednesday shares of Allergan Plc fell by 0.67% to close the day at $208.39.

The post Allergan plc Ordinary Shares (NYSE:AGN)’s Botox Gets FDA Approval For Third Indication appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
06:14p Amneal, Impax combine to tackle generic drug pricing pressure
10/16DJALLERGAN : Loses Patent Fight in Federal Court
10/16 ALLERGAN : U.S. District Court for the Eastern District of Texas Issues Adverse ..
10/16 ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
10/16 ALLERGAN : Announces Settlement on RESTASIS 0.05% Patent Litigation with InnoPha..
10/13 ALLERGAN : to Present Data from More Than 20 Abstracts at the 2017 Fall Clinical..
10/12 ALLERGAN : Announces Settlement on RESTASIS® (Cyclosporine Ophthalmic Emulsion) ..
10/12 ALLERGAN : FDA Accepts Supplemental New Drug Application sNDA filing for AVYCAZ®..
10/12 ALLERGAN : To Present New Data From Its Anti-Infectives Portfolio At IDWeek 2017..
10/12 ALLERGAN : Announces that the FDA Accepts New Drug Application for Ulipristal Ac..
More news
News from SeekingAlpha
12:08p Syndax in-licenses blood cancer candidates from Vitae Pharma
10:36a UBS softens outlook on Allergan after adverse Restasis patent ruling; shares ..
09:06a Allergan Punished After Judge Invalidates Restasis Patents
03:50a ALLERGAN : How Bad Is It?
10/16 Allergan Restasis patent-stoked selloff overdone - JPMorgan
Financials ($)
Sales 2017 15 892 M
EBIT 2017 7 624 M
Net income 2017 -3 931 M
Debt 2017 24 536 M
Yield 2017 1,47%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,72x
EV / Sales 2018 5,33x
Capitalization 66 330 M
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 263 $
Spread / Average Target 32%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-2.14%66 330
JOHNSON & JOHNSON18.42%365 346
NOVARTIS13.23%226 956
ROCHE HOLDING LTD.5.20%215 359
PFIZER11.88%214 265